AstraZeneca (NYSE:AZN) announced its fourth-quarter and 2019 full-year financial results on Friday morning. While the company reported impressive sales growth in a number of its top-selling drugs, investors are worried that the novel coronavirus outbreak could significantly eat away at the company’s 2020 sales.Revenue came in at $6.7 billion, a 3.8% increase from last year. Product sales accounted for the majority of this figure, around $6.25 billion, which is up a healthy 8.4% from Q4 2018. The remaining $414 million came from collaboration revenue, which has shrunk by 36.2%. In terms of specific products, AstraZeneca’s non-small cell lung cancer drug Tagrisso brought in $884 million in revenue, a 49% increase from last year. Another top performer for the company, a cancer drug called Imfinzi, is up 62% from Q4 2018 and brought in $424 million.Despite strong growth in a number of the company’s drugs, the bottom line remains less than impressive. Profit after tax came in at only $277 million for the quarter, which is a 72% decline from last year.The pharmaceutical giant also warned that 2020 revenues could be significantly impacted due to the coronavirus epidemic. Chinese sales have been a major revenue driver for AstraZeneca, which grew 35% in 2019 alone. Considering China is the AstraZeneca’s fastest-growing market, the company’s growth prospects for 2020 could be significantly hampered by further outbreaks of the coronavirus.The company’s 2020 guidance expects high-single-digit to low-double-digit percentage increases in revenue assuming that the coronavirus doesn’t last more than a few months.